Connect with us

Technology

Nicolas S. Piuzzi, MD, Presented Kappa Delta Young Investigator Award for Research on Employing Data Analytics to Improve Patient Outcomes

Published

on

ROSEMONT, Ill., Feb. 7, 2025 /PRNewswire/ — Nicolas S. Piuzzi, MD, was recognized as the 2025 Kappa Delta Young Investigator Award winner for research showing how leveraging advanced analytics with personalized outcome prediction tools can optimize the outcomes and satisfaction of total hip and knee arthroplasty (THA, TKA) for patients. Utilizing patient-reported outcomes measures (PROMs) can help clinicians identify risk factors and predict outcomes more accurately, allowing for tailored interventions at the patient level. The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old or no more than seven years beyond training.

To read more about the award, please click here.

Each year, approximately 790,000 TKAs and 544,000 THAs are performed in the U.S., numbers that are expected to grow due to an aging population.[i] PROMs have become an increasingly important measure for total joint arthroplasty (TJA) as health care systems shift toward a value-based model, especially in light of the fact that the Centers for Medicare & Medicaid Services (CMS) implemented guidelines for 2025 that will require hospitals to submit pre- and postoperative PROMs data for THA and TKA to receive full CMS reimbursement. PROMs provide insights into patients’ perspectives on their pain, function and quality of life before and after surgery.

Even with successful surgical outcomes following THA and TKA, 10 to 20% of patients report persistent pain, functional limitations or unmet expectations one year following surgery.[ii] Dr. Piuzzi and his colleagues from Cleveland Clinic Adult Reconstruction Research (CCARR) from the Department of Orthopaedic Surgery, Cleveland Clinic, theorized that incorporating data analytics and PROMs could help practitioners identify patients who may be at a higher risk for poor outcomes, potentially closing the gap between surgical outcomes and patient satisfaction.

“Musculoskeletal conditions, such as osteoarthritis, represent the leading cause of disability and impose a growing economic and health burden on our society,[iii]” said Dr. Piuzzi, associate staff and director of research, Cleveland Clinic Adult Reconstruction Research Department of Orthopaedic Surgery, and Cleveland Clinic Musculoskeletal Research Center co-director. “Despite affecting over one-third of the U.S. population and accounting for hundreds of billions in annual health-care costs, these conditions remain underfunded in research, highlighting an urgent need for action to advance innovative treatments and improve patient outcomes. Specifically, hip and knee arthroplasties can be very costly for our healthcare system and patients. While these procedures have been performed successfully for many years, we asked ourselves how we could incorporate the same level of data that other industries use to give patients a detailed assessment of what they can expect with joint replacement and to determine which risk factors need to be included in the modeling.”

Creating a Comprehensive Data Collection System
In 2015, the Cleveland Clinic developed the Orthopaedic Minimal Data Set Episode of Care database as a comprehensive PROMs data collection platform specifically for TJA.[iv] Patient demographics, general health PROMs, joint-specific PROMs, and disease severity and treatment details are captured from patients and surgeons at specific points in time following surgery. Integrating PROMs collection into the routine clinical workflow achieved a high baseline completion rate (>97%) for TJA procedures. Passive and active follow-up methods, including automated email reminders, text messages and electronic health record messages, are used to ensure patients are reached. If patients do not respond, telephone calls and personalized mailed letters are sent. A study published by the research team shows passive measures captured one-year PROMs for 38% of the THA cohort and 40% of the TKA cohort.[v] A significant portion of patients ― 40% for THA and 41% for TKA ― required more active follow-up to complete their postoperative PROMs. The study showed the need for a multimodal approach to patient follow-up to collect PROMs data.

Preoperative PROMs Phenotypes Lead to Individualized Approach
Using preoperative PROMs phenotypes that incorporate pain, function and mental health provides for a more accurate representation of each patient’s unique needs and risk factors, allowing surgeons to individualize the approach and better predict outcomes after TJA.

In a study of 4,034 primary THA patients, Dr. Piuzzi and the research team defined eight distinct phenotypes based on combinations of above or below median scores for Hip Disability and Osteoarthritis Outcome Score (HOOS) pain, HOOS-Physical Function Shortform (HOOS-PS), and Veterans RAND 12 Item Health Survey-Mental Health Summary Measure (VR-12 MCS), which is a self-administered health survey that captures physical and mental health aspects.[vi] The study found that phenotypes characterized by lower-than-median VR-12 MCS scores were significantly associated with increased dissatisfaction at one year, regardless of pain or function scores. Patients with the phenotype representing below-median scores across all three PROMs had the highest odds of dissatisfaction compared to the reference phenotype.

By identifying patients with high-risk phenotypes, clinicians can develop targeted interventions to optimize patients’ preoperative condition and manage expectations.

“The variation between the different phenotypes is a 9 to 10% risk of failure to a 25% risk of failure related to patient satisfaction and perception of improvement,” said Dr. Piuzzi. “This gives practitioners a very powerful tool to counsel patients and address some of the risk factors for each patient. If you have a patient in the high-risk group who is having mental health issues or poor function, clinicians need to set expectations and address some of the issues to mitigate risk factors. It is very applicable as it is readily available to everyone, but we need to ensure the data is collected, analyzed and implemented.”

Developing a Predictive Model
With value-based health care becoming more important, there is a need for a data-driven, standardized approach to guide the shared decision-making process in TJA. Integrating PROMs and relevant patient characteristics into a comprehensive predictive model allows for the development of a personalized outcome prediction tool that can estimate the likelihood of improved pain, function and quality of life after surgery for individuals.

The Cleveland Clinic research team built a tool for TKA that incorporated separate models for predicting length of stay; 90-day readmission; and one-year improvements in Knee Injury and Osteoarthritis Outcome Score (function and quality of life sub-scores). These models include a range of patient factors ― demographics, comorbidities, baseline PROMs and laboratory values ― and allow the predictive tool to consider modifiable risk factors. The personalized outcome prediction tool demonstrated high accuracy in predicting outcomes for new patients. This demonstrates the potential for using data-driven models to provide patients and surgeons with individualized estimates of expected outcomes based on preoperative characteristics and PROMs.

About the Kappa Delta Awards
The Kappa Delta Awards, the first of which was established by the Kappa Delta Sorority and awarded in 1950, are presented by the AAOS to persons who have performed research in orthopaedic surgery that is of high significance and impact. The sorority would later add two more awards, valued at $20,000 each. Two awards are named for the sorority national past presidents who were instrumental in the creation of the awards: Elizabeth Winston Lanier and Ann Doner Vaughn. The third is known as the Young Investigator Award.

For more information, please visit aaos.org/kappadelta. Learn more about the Kappa Delta Foundation, here.

About the AAOS
With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal health care issues; and it leads the health care discussion on advancing quality.

Follow the AAOS on Facebook, X, LinkedIn and Instagram.

________________________________________
i American College of Rheumatology. Joint Replacement Surgery. Published February 2024. Accessed Dec. 18, 2024. https://rheumatology.org/patients/joint-replacement-surgery
ii Orr MN, Klika AK, Emara AK, et al. 2022. Dissatisfaction After Total Hip Arthroplasty Associated with Preoperative Patient-Reported Outcome Phenotypes. J. Arthroplasty 37(7S):S498–S509.
iii McConaghy K, Klika AK, Apte SS, Erdemir A, Derwin K, Piuzzi NS. A Call to Action for Musculoskeletal Research Funding: The Growing Economic and Disease Burden of Musculoskeletal Conditions in the United States Is Not Reflected in Musculoskeletal Research Funding. J Bone Joint Surg Am. 2023 Mar 15;105(6):492-498.
iv OME Cleveland Clinic Orthopaedics. Implementing a Scientifically Valid, Cost-Effective, and Scalable Data Collection System at Point of Care: The Cleveland Clinic OME Cohort. J Bone Joint Surg Am. 2019 Mar 6;101(5):458-464.
v Rullán PJ, Pasqualini I, Zhang C, et al. 2024. How to Raise the Bar in the Capture of Patient-Reported Outcome Measures in Total Joint Arthroplasty: Results from Active and Passive Follow-up Measures. J. Bone Joint Surg. Am. 106(10):879–890.
 vi Emara AK, Orr MN, Klika AK, et al. 2022. When is Surgery Performed? Trends, Demographic Associations, and Phenotypical Characterization of Baseline Patient-Reported Outcomes Before Total Hip Arthroplasty. J. Arthroplasty 37(6):1083–1091.e3.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nicolas-s-piuzzi-md-presented-kappa-delta-young-investigator-award-for-research-on-employing-data-analytics-to-improve-patient-outcomes-302370799.html

SOURCE American Academy of Orthopaedic Surgeons

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Jack Henry’s Annual Survey of Financial Institutions Highlights Priorities Amid Economic Uncertainty and a New Hybrid Monetary Era

Published

on

By

Banks and credit unions plan to increase technology spending, led by investments in AI, digital banking, and data analytics

MONETT, Mo., April 28, 2026 /PRNewswire/ — Banks and credit unions are prioritizing operational efficiency, deposit growth, and new payment capabilities as they navigate economic uncertainty and increasing technological complexity, according to findings from Jack Henry’s eighth annual Strategy Benchmark.

Jack Henry® (Nasdaq: JKHY) surveyed 193 executives from financial institutions using Jack Henry solutions. The survey highlights the industry’s most pressing strategic priorities, top concerns, and technology investment plans for the next two years.

“Banks and credit unions have finally recognized their biggest competitive threat in Big Fintech and Big Crypto,” says Lee Wetherington, Senior Director of Corporate Strategy and lead author of the benchmark. “As we enter a new hybrid monetary era, the game is changing and charter franchises are under attack. The goal of strategy is no longer simply to win but to ensure you’re competing to win the right game.”

The vast majority of financial institutions plan to increase technology spending, with 88% expecting to raise their tech budgets over the next two years, up from 76% last year. Four in 10 institutions (41%) plan increases of 6% to 10%, compared with 33% a year ago. Artificial intelligence (48%) is the top planned technology investment for the first time, followed by digital banking (38%) and data analytics (32%). While banks remain focused on growing deposits (64%) as their top strategic priority in 2026-2027, credit unions (40%) continue to place outsized emphasis on acquiring younger accountholders (Gen Z/Alpha).

“Financial institutions are in a high-stakes race for Gen Z and small business,” says Jennifer Geis, Senior Strategic Advisor of Corporate Strategy at Jack Henry and Managing Editor of the study. “Given Gen Z now drives most small-business formation—and given small-business deposits are 4-5X larger than retail—understanding and meeting the unique needs of “bizumers” is key to growth, whether you frame it in terms of deposits or demographics.”

Among the highlights from the survey:

PaymentsMore than nine out of 10 CEOs (94%) plan to add new payment services within the next two years, yet only 36% have a formal payments strategy in place.More than four out of five (82%) financial institutions plan to incorporate tap-to-pay as part of their strategy to add younger accountholders.Nearly half (47%) of CEOs plan to embed payments into their digital banking experience over the next two years.Small Business FocusThree out of four CEOs say they plan to expand services for small- and medium-sized businesses (SMBs).The most common planned addition is payment services, including FedNow®, request for payment, and tap-to-pay. 
 Cryptocurrency18% of CEOs plan to support stablecoins, tokenized money, and/or cryptocurrency by the end of 2027. This includes:Tokenized deposits/deposit tokensSupport for on-chain wallets for accountholdersAbility to orchestrate, exchange, and settle dollars to and from stablecoins/crypto.However, only 3% of CEOs report having a formal stablecoin strategy in place.
 Getting YoungerThe second most important strategic priority for credit unions (and fourth overall) is adding younger accountholders. It is also one of the top three concerns for CEOs.More than 40% of credit unions have a formal strategy, compared to just 10% of banks.Fintechs and neobanks are considered the biggest competitive threat in this area.Data analytics and AILeveraging data is the 5th most important strategic priority overall among banks and credit unionsPlans to implement AI grew double digits compared to last year1/3 of FIs plan to embed data collection/analysis tools within digital banking

The study’s results are based on an online survey conducted in January and February 2026 of a diverse sample of Jack Henry clients with assets ranging from less than $500 million to more than $5 billion. Download the eBook to learn more.

About Jack Henry & Associates, Inc.®
Jack Henry® (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower approximately 7,400 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at jackhenry.com.

Statements made in this news release that are not historical facts are “forward-looking statements.” Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, those discussed in the Company’s Securities and Exchange Commission filings, including the Company’s most recent reports on Form 10-K and Form 10-Q, particularly under the heading “Risk Factors.” Any forward-looking statement made in this news release speaks only as of the date of the news release, and the Company expressly disclaims any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/jack-henrys-annual-survey-of-financial-institutions-highlights-priorities-amid-economic-uncertainty-and-a-new-hybrid-monetary-era-302756018.html

SOURCE Jack Henry & Associates, Inc.

Continue Reading

Technology

CorroHealth Honored As Stevie® Award Winner In 2026 American Business Awards®

Published

on

By

PLANO, Texas, April 28, 2026 /PRNewswire/ — Leading revenue cycle technology company CorroHealth was named the winner of a Silver Stevie® Award in the Health Provider category in The 24th Annual American Business Awards®.

The American Business Awards are the U.S.A.’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. This year, the program received more than 3,600 nominations from organizations across virtually every industry.

“We are honored to receive this prestigious award and to be recognized alongside many esteemed American business leaders,” said Pat Leonard, CEO of CorroHealth. “This acknowledgement reflects CorroHealth’s ongoing commitment to the healthcare industry, serving as the leading revenue cycle technology company built for the future of healthcare finance.”

CorroHealth earned recognition for its mission and purpose, transforming healthcare operations and driving innovation to deliver better outcomes for hospitals and health systems. The company was selected after a methodical nomination process and careful evaluation of its industry impact and dedication to bridging the gap between patient care and financial performance.

More than 250 professionals worldwide participated in the judging process to select this year’s Stevie Award winners. One judge who evaluated the nomination stated, “CorroHealth’s blend of expert driven services and AI-powered platforms delivers measurable, enterprise scale financial gains that far exceed industry norms.” The judges also recognized the company as a leader in innovation and operational excellence within the healthcare financial technology sector.

To learn more about CorroHealth, visit corrohealth.com.

About CorroHealth 
CorroHealth, the leading healthcare technology and revenue cycle management company that helps providers and payers improve financial performance through automation, data-driven analytics, and clinically led expertise. CorroHealth delivers integrated, scalable solutions that support complex reimbursement and documentation workflows, backed by a global workforce operating in more than 10 locations, including the United States, United Kingdom, India, and the United Arab Emirates. The company was recently named one of the “Top Places to Work in Healthcare in 2026” by Becker’s Healthcare and a Great Place To Work® Certified™ in India for the second time in two years. Further information is available at corrohealth.com.

About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the new Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes, as well as the people behind them, the Stevies recognize outstanding workplace performance worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Media Contact:
CorroHealth
Mellissa Gardner, Chief Marketing and Strategy Officer
mellissa.gardner@corrohealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/corrohealth-honored-as-stevie-award-winner-in-2026-american-business-awards-302755949.html

SOURCE CorroHealth

Continue Reading

Technology

Singular Genomics Names John Stark as Chief Executive Officer as Company Builds on Spatial Platform Momentum

Published

on

By

SAN DIEGO, April 28, 2026 /PRNewswire/ — Singular Genomics Systems, Inc. today announced the appointment of John Stark as Chief Executive Officer. This leadership transition comes as Singular builds on the launch of its market-leading spatial platform and enters its next phase, focused on expanding adoption, deepening strategic partnerships, and increasing the impact of multimodal spatial data across translational research, drug development, and future clinical applications. Josh Stahl will transition to a new role as Independent Director on the Board.

“With Singular’s G4X platform now successfully on the market, the company is positioned to realize spatial pathology’s potential across translational research and clinical applications,” said Allison Ballmer, Chair of the Board. “Josh strengthened Singular and repositioned the company’s technology, culminating in the successful launch of the G4X platform. John’s leadership experience will now help scale the business and capitalize on the opportunity to drive precision medicine forward.”

John brings more than 25 years of experience commercializing innovative technologies while scaling organizations and raising capital. Most recently, John served as Chief Executive Officer of Resolve Biosciences, a spatial biology platform company, where he drove partnerships and routine use across the translational, drug development, and clinical research markets. Prior to Resolve, John served as Chief Executive Officer of Quantum-Si, a next-generation single-molecule protein sequencing platform company, and Chief Executive Officer of Celsee, a single-cell genomics platform company acquired by Bio-Rad in 2020. Earlier in his career, he held senior leadership positions at Life Technologies, Pacific Biosciences, and Affymetrix.

“Singular has built a competitive spatial platform and a strong foundation in a rapidly evolving market,” said John Stark, CEO. “I’m excited to build on that momentum – deepening partnerships, scaling adoption, and unlocking broader value from spatial data across research, drug development, and precision medicine.”

“We thank Josh Stahl for building an exceptional foundation for Singular, and welcome John Stark, who brings a long history of commercial leadership to the company,” said Andrew ElBardissi, Partner at Deerfield Management. “We remain confident in Singular’s technology, market opportunity, and path to leadership in precision medicine and are committed to supporting the company’s continued growth.”

About Singular Genomics

Singular is a life science technology company focused on delivering high-throughput spatial pathology solutions to advance precision medicine. The company’s G4X™ Spatial Sequencer enables scalable, multiomic analysis directly in tissue, combining performance, throughput, and cost efficiency to support translational research, AI-driven insights, and clinical developments. Singular is headquartered in San Diego, California.

Forward-Looking Statements

Certain statements contained in this press release, other than statements of historical fact, may constitute forward-looking statements within the meaning of the federal securities laws. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Singular Genomics undertakes no obligation to update forward-looking statements, except as required by law.

Media Contact
Darius Fugere
dariusf@singulargenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/singular-genomics-names-john-stark-as-chief-executive-officer-as-company-builds-on-spatial-platform-momentum-302754834.html

SOURCE Singular Genomics

Continue Reading

Trending